All In MedTech

Device Trial Radar · NCT07911527

The Edison™ System for Treatment of Renal Tumors Using Histotripsy (Histo-Renal Trial)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Dec 31, 2028

Study completion Feb 28, 2029

Sponsor

Lead sponsor
Chinese University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 2, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective single-center, single-arm, feasibility trial designed to evaluate the safety of the HistoSonics Histotripsy System for treatment of renal tumors. The type of design is exploratory and is considered interventional. Following histotripsy, subjects will undergo imaging ≤ 72 hours post-index procedure. Additionally, subjects will be followed at 1 month, 3 months, 6 months and 12 months timepoints.

Conditions

  • Renal Tumors

Interventions

  • HistoSonics® Edison System (US)Device

    Patient will be arranged to admit to the Chinese University of Hong Kong Medical Centre (CUHKMC), assessed by anaesthetist before the operation, and go through histotripsy treatment under general anaesthesia in CUHK Medical Centre (CUHKMC). After general anaesthesia with intubation, the patient is placed in left or right lateral position. A water tank will be placed on top of the patient's loin area. The histotripsy ultrasound and treatment head will be placed inside the water tank and image-guided histotripsy ablation of the kidney tumor will be performed. The overall anaesthesia time is estimated to be 60-75 minutes and ablation time is 10-20 minutes, respectively. The expected length of hospital stay is 1 day after operation. Patient will be followed up and assessed up to 1 year after the procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary technique efficacyTime frame: at 90 days after treatment
  2. Primary safety endpointTime frame: at 30 days after the histotripsy procedure

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.